The B7x pathway in the tumor microenvironment
The B7x pathway in the tumor microenvironment
批准号:
9259959
负责人:
Xingxing Zang
金额:
$34.65万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-01 至 2019-03-31
关键词:
AddressB7-DC antigenCD276 geneCD28 geneCD80 geneCancer PatientCell LineCell physiologyCellsClinicalClinical DataClinical ResearchClinical TrialsCrystallizationCytotoxic T-Lymphocyte-Associated Protein 4DataDevelopmentDisease ProgressionEffectivenessEvolutionFamilyFutureGenerationsGenesGoalsHistamine H3 ReceptorsHumanImmuneImmune EvasionImmune responseImmunosuppressive AgentsImmunotherapeutic agentImmunotherapyInvestigationIslet CellKineticsKnock-outKnockout MiceKnowledgeLeadLymphoid TissueMalignant NeoplasmsMalignant neoplasm of ovaryMalignant neoplasm of prostateMammary NeoplasmsMissionModelingMonoclonal AntibodiesMusMyelogenousNeoplasm MetastasisOutcomeOutcomes ResearchPDCD1LG1 genePancreasPathway interactionsPatientsPhasePositioning AttributeProteinsPublic HealthPublishingRIPK1 geneReagentRegulatory T-LymphocyteResearchResistanceRoleStructureSuppressor-Effector T-LymphocytesSystemT-Cell ActivationT-LymphocyteTestingTherapeuticTransgenic MiceTranslatingTumor BurdenTumor ImmunityUnited States National Institutes of HealthVTCN1 geneWorkcancer cellcancer immunotherapycohortdesignimmunoregulationin vivoinnovationinsightmelanomamembermouse modelmultidisciplinaryneoplastic cellnovelnovel therapeuticsoverexpressionprogramspublic health relevancereceptorskillstherapeutic targettooltumortumor growthtumor microenvironmenttumor progressiontumorigenesis
中文摘要
描述(由申请人提供):癌症免疫治疗的关键问题之一是确定肿瘤生长不同阶段的主要逃逸机制,并设计克服这些机制的方法。我们已经确定B7 x作为一个不良的特性的成员B7家族的T细胞共刺激和共抑制。我们的临床数据显示,在多种人类癌症中观察到B7 x的异常表达,并且通常与不良的临床结果相关。该项目的假设是B7 x是肿瘤微环境中的关键免疫逃避途径,阻断该途径可产生治疗性肿瘤免疫。在我们已发表的癌症患者临床研究和我们强有力的鼠肿瘤模型初步数据的指导下,将通过追求三个具体目标来检验这一假设:1)阐明肿瘤表达的B7 x在疾病进展中的功能后果; 2)确定宿主细胞表达的B7 x对肿瘤进展的机制贡献;和3)通过靶向B7 x途径产生治疗性肿瘤免疫。我们已经开发了许多新的工具,并组建了一个具有互补技能的多学科团队,这为我们提供了应对挑战和实现目标的独特机会。这项研究的结果将为肿瘤微环境中B7 x通路的免疫逃避机制提供新的见解,并为未来新免疫疗法的临床设计提供基础。
英文摘要
DESCRIPTION (provided by applicant): One of the key issues in cancer immunotherapy is to identify the dominant escape mechanisms during different phases of tumor growth and to devise ways to overcome them. We have identified B7x as a poorly characterized member of the B7 family of T cell costimulation and coinhibition. Our clinical data have revealed that aberrant expression of B7x is observed in a variety of human cancers and is often associated with poor clinical outcome. The hypothesis of this project is that B7x is a critical immune evasion pathway within the tumor microenvironment and blockade of this pathway generates therapeutic tumor immunity. Guided by our published clinical research with cancer patients and our strong preliminary data with murine tumor models, this hypothesis will be tested by pursuing three specific aims: 1) Elucidation of the functional consequence of tumor-expressed B7x in disease progression; 2) Determination of mechanistic contribution of host cell-expressed B7x to tumor progression; and 3) Generation of therapeutic tumor immunity by targeting the B7x pathway. We have generated a number of novel tools and have assembled a multi-disciplinary team with complementary skill sets, which provides us with unique opportunities to address challenges and realize goals. The outcomes of this research will provide novel insights into immune evasion mechanisms of the B7x pathway in the tumor microenvironment and provide the basis for future clinical design of a new immunotherapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A New Immune Checkpoint Pathway in Human Bladder Cancer
-
批准号:10583686
-
项目类别:
-
资助金额:$54.55万
-
财政年份:2022
-
负责人:Xingxing Zang
-
依托单位:
A new immune checkpoint pathway in human bladder cancer
-
批准号:10811317
-
项目类别:
-
资助金额:$2.38万
-
财政年份:2022
-
负责人:Xingxing Zang
-
依托单位:
Mechanisms and Therapies of B7x and B7-H3 in T1D
-
批准号:9769007
-
项目类别:
-
资助金额:$37.58万
-
财政年份:2015
-
负责人:Xingxing Zang
-
依托单位:
Mechanisms and therapies of B7x and B7-H3 in T1D
-
批准号:9029583
-
项目类别:
-
资助金额:$37.58万
-
财政年份:2015
-
负责人:Xingxing Zang
-
依托单位:
Mechanisms and Therapies of B7x and B7-H3 in T1D
-
批准号:9340146
-
项目类别:
-
资助金额:$37.58万
-
财政年份:2015
-
负责人:Xingxing Zang
-
依托单位:
Mechanisms and Therapies of B7x and B7-H3 in T1D
-
批准号:9149198
-
项目类别:
-
资助金额:$37.58万
-
财政年份:2015
-
负责人:Xingxing Zang
-
依托单位:
The B7x pathways in the tumor microenvironment
-
批准号:10532710
-
项目类别:
-
资助金额:$39.1万
-
财政年份:2014
-
负责人:Xingxing Zang
-
依托单位:
The B7x pathways in the tumor microenvironment
-
批准号:10116632
-
项目类别:
-
资助金额:$39.89万
-
财政年份:2014
-
负责人:Xingxing Zang
-
依托单位:
The B7x pathways in the tumor microenvironment
-
批准号:10738320
-
项目类别:
-
资助金额:$8.07万
-
财政年份:2014
-
负责人:Xingxing Zang
-
依托单位:
The B7x pathway in the tumor microenvironment
-
批准号:8631219
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2014
-
负责人:Xingxing Zang
-
依托单位:
The B7x pathway in the tumor microenvironment
-
批准号:8843234
-
项目类别:
-
资助金额:$5.91万
-
财政年份:2014
-
负责人:Xingxing Zang
-
依托单位:
The B7x pathways in the tumor microenvironment
-
批准号:10307635
-
项目类别:
-
资助金额:$39.1万
-
财政年份:2014
-
负责人:Xingxing Zang
-
依托单位:
NCI Diversity Supplement
-
批准号:10531284
-
项目类别:
-
资助金额:$4.82万
-
财政年份:2014
-
负责人:Xingxing Zang
-
依托单位:
Tumor-expressed immune checkpoint B7x-mediated resistance to anti-CTLA-4 therapy.
-
批准号:10429780
-
项目类别:
-
资助金额:$37.8万
-
财政年份:2014
-
负责人:Xingxing Zang
-
依托单位:
The B7x pathways in the tumor microenvironment
-
批准号:10778670
-
项目类别:
-
资助金额:$37.04万
-
财政年份:2014
-
负责人:Xingxing Zang
-
依托单位:
New T Cell Coinhibitory Pathway and Type 1 Diabetes
-
批准号:8000981
-
项目类别:
-
资助金额:$9.0万
-
财政年份:2009
-
负责人:Xingxing Zang
-
依托单位:
New T Cell Coinhibitory Pathway and Type 1 Diabetes
-
批准号:8139434
-
项目类别:
-
资助金额:$0.25万
-
财政年份:2008
-
负责人:Xingxing Zang
-
依托单位: